USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SIGNUM BIOSCIENCES
Address:
7 DEER PARK DR, STE H
MONMOUTH JUNCTION, NJ
Phone:
N/A
URL:
N/A
EIN:
101061574
DUNS:
144196354
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,307,558.00 4
SBIR Phase II $6,219,380.00 3

Award List:

A Novel Class of Non Steroidal Anti-Inflammatories

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$298,744.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs, such as N-acetyl-S-farnesyl-L-cysteine (AFC) modulate heterotrimeric G- protein and Ras-related signaling pathways, representing a potentially novel class of topical anti- inflammatory compounds. Using mouse models for acute… More

A Topical Non Steroidal Anti-inflammatory for Rosacea

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,568,458.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Isoprenylcysteine (IPC) analogs modulate heterotrimeric G-protein coupled receptor (GPCR) signaling pathways, representing a novel class of topical anti-inflammatory compounds whose action is restricted to the site of a pplication. Studies performed in the Phase… More

A Novel Class of Therapeutic Agents for the Treatment of Skin Diseases Associated

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$356,919.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): N-acetyl-S-famesyl-L-cysteine (AFC) and its derivatives (isoprenylcysteine (IPC) analogs) represent a novel class of topically absorbed NSAIDs whose activity is restricted to the site of application with no detectable s ystemic effects and no adverse affects such… More

A Novel Class of Topical Pleitropic Anti-Acne Therapeutics

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$327,178.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Acne is a multifactorial disease affecting ~50 million people in the US. Three main factors contribute to the pathogenesis of acne; 1) P. acnes growth 2) P. acnes-induced inflammation and 3) overproduction of sebum, all targets for therapeutic intervention.… More

Phosphoprotein phosphatase 2A, a new target for Alzheimer's Disease interventio

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$324,717.00
Agency:
HHS
Principal Investigator:
Steven Braithwaite
Abstract:
DESCRIPTION (provided by applicant): Abnormal hyperphosphorylation of tau plays an important role in Alzheimer's disease (AD) and other tauopathies. Current therapeutic approaches with focus on tau kinases (e.g. GSK-3, MAPK, cdk5, CK-1, PKA, CaMKII) are hi ndered by multiple and redundant tau… More

A Topical Non Steroidal Anti-inflammatory for Rosacea

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,975,892.00
Agency:
HHS
Principal Investigator:
Braham Shroot – 732-329-6344
Abstract:
DESCRIPTION (provided by applicant): Rosacea is a chronic dermatological condition characterized by flushing, erythema, papules, pustules, inflammatory nodules and telangiectasia. Although disease etiology remains unclear, skin inflammation has been identified as the main contributor to disease… More

A Topical Non-steroidal Anti-inflammatory for Atopic Dermatitis

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,675,030.00
Agency:
HHS
Principal Investigator:
Braham Shroot – 732-329-6344
Abstract:
DESCRIPTION (provided by applicant): Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young children. Current treatments are associated with a wide range of side effects therefore development of novel therapeutic agentsthat are efficacious and have an improved… More